Capsule Formulation
    4.
    发明申请
    Capsule Formulation 审中-公开
    胶囊制剂

    公开(公告)号:US20100285121A1

    公开(公告)日:2010-11-11

    申请号:US12735383

    申请日:2008-12-29

    摘要: The present invention provides the following capsule preparation, which is superior in dissolution property and the like of a pharmaceutically active ingredient and contains liquid and solid pharmaceutically active ingredients: a seamless capsule containing liquid and solid pharmaceutically active ingredients, wherein the liquid pharmaceutically active ingredient is encapsulated in the form of a liquid pharmaceutical composition, and the solid pharmaceutically active ingredient is dispersed in a capsule shell layer.

    摘要翻译: 本发明提供以下胶囊制剂,其药学活性成分的溶解性等优异,并且含有液体和固体药物活性成分:含有液体和固体药物活性成分的无缝胶囊,其中液体药物活性成分为 以液体药物组合物的形式包封,并且固体药物活性成分分散在胶囊壳层中。

    SEAMLESS CAPSULE
    5.
    发明申请
    SEAMLESS CAPSULE 审中-公开
    无缝胶囊

    公开(公告)号:US20100119598A1

    公开(公告)日:2010-05-13

    申请号:US12452374

    申请日:2008-06-27

    摘要: The present invention aims to provide a seamless capsule free of an interfacial tension modifier and a gelling agent. The present invention provides a shell formed by a shell composition containing gelatin and a plasticizer, but free of an interfacial tension modifier and a gelling agent, and a seamless capsule comprising a capsule content free of an interfacial tension modifier and a gelling agent.

    摘要翻译: 本发明旨在提供一种无界面张力调节剂和胶凝剂的无缝胶囊。 本发明提供一种由含有明胶和增塑剂但不含界面张力调节剂和胶凝剂的壳组合物形成的壳,以及包含不含界面张力调节剂和胶凝剂的胶囊含量的无缝胶囊。

    SUSTAINED RELEASE PREPARATION
    6.
    发明申请
    SUSTAINED RELEASE PREPARATION 审中-公开
    持续发布准备

    公开(公告)号:US20110045028A1

    公开(公告)日:2011-02-24

    申请号:US12516536

    申请日:2007-11-29

    摘要: Disclosed is a sustained-release preparation which is prepared by shaping a granule comprising a blood coagulation factor Xa inhibitor and a mixture of at least two hydrophilic polymers. Also disclosed is a pharmaceutical composition comprising a combination of the sustained-release preparation and an immediate release preparation comprising a blood coagulation factor Xa inhibitor. It becomes possible to provide a controlled release preparation comprising a blood coagulation factor Xa inhibitor for the prevention or treatment of thrombosis, which can control the activity of blood coagulation factor Xa for a long term and is excellent in convenience and compliance. It is also becomes possible to provide a method for producing the controlled release preparation.

    摘要翻译: 公开了一种缓释制剂,其通过使包含凝血因子Xa抑制剂和至少两种亲水性聚合物的混合物的颗粒成形而制备。 还公开了包含缓释制剂和包含凝血因子Xa抑制剂的速释制剂的组合的药物组合物。 可以提供一种控制释放制剂,其包含凝血因子Xa抑制剂,用于预防或治疗血栓形成,其可以长期控制凝血因子Xa的活性,并且方便性和顺应性优异。 也可以提供一种制备控释制剂的方法。

    Solid preparation
    7.
    发明申请
    Solid preparation 审中-公开
    固体制剂

    公开(公告)号:US20090208584A1

    公开(公告)日:2009-08-20

    申请号:US11921664

    申请日:2006-06-09

    IPC分类号: A61K9/14 A61K47/38 A61K31/538

    摘要: The solid preparation of the present invention aims at providing a solid preparation superior in the stability during production and preservation even when a poorly water-soluble substance having a low melting point is contained in a large amount, and also superior in the disintegration property and release property of a poorly water-soluble substance having a low melting point, after oral administration, and is characterized by the following 1) to 3): 1) containing a poorly water-soluble substance having a low melting point, a saccharide, and a cellulose selected from a crystalline cellulose and a low-substituted hydroxypropylcellulose, 2) a saccharide/cellulose weight ratio exceeding 2, and 3) a cellulose content of not less than 5 wt %.

    摘要翻译: 本发明的固体制剂的目的在于提供即使在大量含有低熔点的难溶性水溶性物质的情况下,在制造和保存中的稳定性方面也优异的固体制剂,并且还具有优异的崩解性和脱模性 口服后具有低熔点的水溶性差的物质的性质,其特征在于以下1)〜3):1)含有低熔点的水难溶性物质,糖类和 选自结晶纤维素和低取代羟丙基纤维素的纤维素,2)糖/纤维素重量比超过2,和3)纤维素含量不小于5重量%。

    Method for producing pharmaceutical tablet
    9.
    发明授权
    Method for producing pharmaceutical tablet 有权
    生产药片的方法

    公开(公告)号:US08927011B2

    公开(公告)日:2015-01-06

    申请号:US12601158

    申请日:2008-05-20

    摘要: A process for advantageously producing tablets having an improved release property and an excellent stability to change with time is provided. The process is for producing tablets containing a morphinan compound represented by the Formula (I) below or pharmaceutically acceptable acid addition salt thereof and an acidic substance such as fumaric acid, maleic acid or adipic acid, and characterized in that the morphinan compound or a pharmaceutically acceptable acid addition salt thereof is granulated by wet granulation together with (an) excipient(s) prior to adding the acidic substance thereto.

    摘要翻译: 提供了一种有利地制备具有改善的释放性能和优异的随时间​​变化的稳定性的片剂的方法。 该方法用于制备含有由下式(I)表示的吗啡喃化合物或其药学上可接受的酸加成盐和酸性物质如富马酸,马来酸或己二酸的片剂,其特征在于吗啡喃化合物或药学上可接受的盐 在将酸性物质加入其中之前,其可接受的酸加成盐与(a)赋形剂一起通过湿法制粒造粒。